About Us

The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.

We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.

Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.

JDD reaches around 13,760 dermatology healthcare professionals and has been recognized as the official partner of the Skin of Color Update (SOCU) and the ODAC Dermatology Aesthetic and Surgical (ODAC) conferences.

The extremely current and practical editorial content of JDD results in high readership and maximum exposure among the dermatology community.

Our Mission is Excellence through Peer Review: To educate physicians, optimize patient outcomes, and disseminate key scientific information.

JDD is published by SanovaWorks.

In the News

April 2, 2026 in Featured Articles, JDD in the Media, Latest News

Dermatology Roundup: NPF Clarifies Definition of Psoriasis Disease Severity

Survey reveals higher likelihood of reported delays in accessing melanoma care among patients with skin of color The National Psoriasis Foundation (NPF) has a new position statement that clarifies the…
Read More
January 22, 2026 in Featured Articles, JDD in the Media, Latest News

JDD in the News: Skin and Hair Reactions from GLP-1 Agonists

Medscape highlighted a January Journal of Drugs in Dermatology study on the incidence of skin and hair effects from GLP-1 agonists. The study, “Cutaneous Adverse Events Associated With GLP-1 Receptor…
Read More
January 10, 2026 in Featured Articles, JDD in the Media, Latest News

JDD in the News: Isotretinoin & Inflammatory Bowel Disease

Medscape featured a December Journal of Drugs in Dermatology study on the link between isotretinoin and inflammatory bowel disease (IBD). The study, “Isotretinoin Does Not Increase the Risk of Inflammatory…
Read More
September 22, 2025 in Atopic Dermatitis, Featured Articles, JDD Highlights, JDD in the Media, The Latest

JDD in the News: Pharmacy Deserts and Affordability Concerns in Atopic Dermatitis Care

Healio profiled a July Journal of Drugs in Dermatology study on the affordability of dermatologist-recommended skincare products for atopic dermatitis. The study, “Socioeconomic Disparities in Gentle Skin Care Access for…
Read More
August 18, 2025 in Featured Articles, JDD Highlights, JDD in the Media, Skincare, The Latest

JDD in the News: Perceived Dermatologic Side Effects of Cancer Treatments

Several media outlets covered an August Journal of Drugs in Dermatology survey on the perceived dermatologic side effects of cancer treatments and how those perceptions could impact a person’s decision…
Read More

Editorial Board

Founder
Perry Robins, MD

Editor-in-Chief
Deborah S. Sarnoff MD